Latest & greatest articles for acyclovir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on acyclovir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on acyclovir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for acyclovir

1. Tratamiento con Aciclovir en Varicela y Herpes Zoster en niños: ¿Cuando y a quién?

Tratamiento con Aciclovir en Varicela y Herpes Zoster en niños: ¿Cuando y a quién? Pediatría Basada en Pruebas: Tratamiento con Aciclovir en Varicela y Herpes Zoster en niños: ¿Cuando y a quién? Blog personal, no ligado a ninguna Sociedad científica profesional. Los contenidos de este blog están especialmente destinados a profesionales sanitarios interesados en la salud infantojuvenil martes, 23 de enero de 2018 Tratamiento con Aciclovir en Varicela y Herpes Zoster en niños: ¿Cuando y a quién (...) exponen estos casos concretos en los que un tratamiento antiviral sobradamente conocido, el Aciclovir, debería ser utilizado. Del texto, de obligada consulta, destacamos lo siguiente: " Varicela en niños sanos con factores de riesgo de padecer un cuadro grave : El tratamiento con aciclovir puede iniciarse en paciente sanos que pertenezcan a grupos de riesgo para desarrollar varicela grave. Niños con enfermedad pulmonar o cutánea crónica en los que la sobreinfección bacteriana puede tener consecuencias

2018 Pediatría Basada en Pruebas

2. Acyclovir

Acyclovir Top results for acyclovir - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for acyclovir The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

3. Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Full Text available with Trip Pro

Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Herpes zoster ophthalmicus affects the eye and vision, and is caused by the reactivation of the varicella zoster virus in the distribution of the first division of the trigeminal nerve. An aggressive management of acute herpes zoster ophthalmicus with systemic antiviral medication is generally recommended as the standard first-line treatment for herpes zoster ophthalmicus infections. Both (...) acyclovir and its prodrug valacyclovir are medications that are approved for the systemic treatment of herpes zoster. Although it is known that valacyclovir has an improved bioavailability and steadier plasma concentration, it is currently unclear as to whether this leads to better treatment results and less ocular complications.To assess the effects of valacyclovir versus acyclovir for the systemic antiviral treatment of herpes zoster ophthalmicus in immunocompetent patients.We searched CENTRAL (which

2016 Cochrane

4. Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines

Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions In the last five years there has been very limited new evidence on the effectiveness of oral antivirals in children with chickenpox, pregnant women

2014 Health Technology Assessment (HTA) Database.

5. Should acyclovir be prescribed for immunocompetent children presenting with chickenpox?

. You wonder whether the prescribing of oral acyclovir would reduce the disease severity and duration compared to the advising of symptomatic control only. Search Strategy Medline 1966 – 07 / 04 using the Ovid interface. The Cochrane Library Issue 2, 2004 [(aciclovir OR acyclovir).mp. AND (chickenpox OR chicken pox).mp.] LIMIT to human AND English language AND all child AND randomised controlled trial. Cochrane "aciclovir and chicken pox" Search Outcome The Medline search found 14 papers of which 3 (...) patient numbers. Clinical Bottom Line Oral acyclovir shortens time to fever reduction and time to no new lesions by one day but has no effect on complication rates secondary to infection. These reductions were only seen if treatment was initiated with 24 hours of rash onset. Use of acyclovir should not currently be recommended in immunocompetent children with chickenpox infection. References Balfour HH Jr, Kelly JM, Suarez CS et al. Aciclovir treatment of varicella in otherwise healthy children

2005 BestBETS

6. Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial. Full Text available with Trip Pro

Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial. To compare New Zealand medical grade kanuka honey with topical aciclovir for the treatment of herpes simplex labialis.Prospective parallel randomised controlled open-label superiority trial.76 community pharmacies across New Zealand between 10 September 2015 and 13 December 2017.952 adults randomised within the first 72 hours of a herpes simplex labialis episode.Random assignment 1 (...) :1 to either 5% aciclovir cream or medical grade kanuka honey (90%)/glycerine (10%) cream, both applied five times daily.The primary outcome was time from randomisation to return to normal skin (stage 7). Secondary outcomes included time from randomisation to stage 4 (open wound), time from stage 4 to 7, maximal pain, time to pain resolution and treatment acceptability.Primary outcome variable: Kaplan-Meier-based estimates (95% CI) for the median time in days for return to normal skin were 8 (8

2019 BMJ open Controlled trial quality: predicted high

7. Efficacy of acyclovir for herpes simplex encephalitis (HSE): a protocol for a systematic review of randomized controlled trials

Efficacy of acyclovir for herpes simplex encephalitis (HSE): a protocol for a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

8. Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting. Full Text available with Trip Pro

Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting. Worldwide, about 90% of people are infected with the herpes simplex virus, 30% of whom will experience recurrent herpes simplex labialis, commonly referred to as 'cold sores', which can last up to 10 days. The most common treatment is aciclovir cream which reduces healing time by just half a day compared with no specific treatment (...) . This is a protocol for a randomised controlled trial (RCT) to determine the efficacy of medical grade kanuka honey-based topical treatment (Honevo) in reducing the healing time and pain of cold sores, compared with topical aciclovir treatment (Viraban).This open-label, parallel-group, active comparator superiority RCT will compare the efficacy of medical grade kanuka honey with 5% aciclovir cream in the treatment of cold sores in the setting of a pharmacy research network of 60 sites throughout New Zealand

2017 BMJ open Controlled trial quality: predicted high

9. Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. Full Text available with Trip Pro

Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. The current recommendations for intravenous (i.v.) acyclovir dosing in obese patients suggest using ideal body weight (IBW) rather than total body weight (TBW). To our knowledge, no pharmacokinetic analysis has validated this recommendation. This single-dose pharmacokinetic study was conducted in an inpatient oncology population. Enrollment was conducted by 1:1 matching of obese patients (>190% of IBW) to normal (...) -weight patients (80 to 120% of IBW). All patients received a single dose of i.v. acyclovir, 5 mg/kg, infused over 60 min. Consistent with current recommendations, IBW was used for obese patients and TBW for normal-weight patients. Serial plasma concentrations were obtained and compared. Seven obese and seven normal-weight patients were enrolled, with mean body mass indexes of 45.0 and 22.5 kg/m(2), respectively. Systemic clearance was substantially higher in the obese than normal-weight patients

2016 Antimicrobial Agents and Chemotherapy

10. Comparison of the Efficacy of Combination Therapy of Prednisolone - Acyclovir with Prednisolone Alone in Bell's Palsy. (Abstract)

Comparison of the Efficacy of Combination Therapy of Prednisolone - Acyclovir with Prednisolone Alone in Bell's Palsy. Bell's palsy is a rapid onset, usually, unilateral paralysis of the facial nerve that causes significant changes in an individual's life such as a decline in personal, social, and educational performance. This study compared efficacy of combined prednisolone and acyclovir therapy with prednisolone alone.This study is a randomized controlled trial conducted on 43 Children (2-18 (...) years old) with Bell's palsy. The first group of 23 patients was treated with prednisolone and the remaining patients were treated with a combination of prednisolone and acyclovir. The required data were extracted, using an informational form based on the House-Brackmann Scale, which grades facial nerve paralysis. The data were analyzed with Mann-Whitney test using SPSS version 16.The mean age of the first and second group were 8.65 ± 5.07 and 8.35 ± 4.92 years, respectively, (p=0.84). Sixty one

2015 Iranian journal of child neurology Controlled trial quality: uncertain

11. Effect of Body Mass on Acyclovir Pharmacokinetics

Effect of Body Mass on Acyclovir Pharmacokinetics Effect of Body Mass on Acyclovir Pharmacokinetics - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Body Mass on Acyclovir Pharmacokinetics (...) Description Go to Brief Summary: Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking acyclovir to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan. Patients receiving acyclovir as standard of care will be enrolled into this study

2012 Clinical Trials

12. Does oral aciclovir improve clinical outcome in immunocompetent children with primary herpes simplex gingivotomatitis?

. The lesions have all appeared within the last 2 days. He has been crying inconsolably over the past 24 h and is refusing food and drink. Considering the current evidence we question whether the use of oral aciclovir is indicated for primary herpes gingivostomatitis in children. Search Strategy Cochrane Library: using "herpes AND gingivostomatitis AND aciclovir/acyclovir", "herpes AND gingivostomatitis", "herpes AND aciclovir", "aciclovir AND gingivostomatitis": one relevant result – "Acyclovir (...) children. Pediatr Emerg Care 2006;22:268–9. Ducoulombier H, Cousin J, Dewilde A, et al. Herpetic stomatitis-gingivitis in children: controlled trial of aciclovir versus placebo. Ann Pediatr (Paris) 1988;35:212–16. Aoki FY, Law BJ, Hammond GW, et al.. Acyclovir suspension for treatment of acute herpes simplex virus gingivostomatitis in children: a placebo controlled double blind trial. Abstract no. 1530. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents

2009 BestBETS

13. Neurologic Acyclovir Toxicity in the Absence of Kidney Injury. (Abstract)

Neurologic Acyclovir Toxicity in the Absence of Kidney Injury. Herpes zoster (zoster) also commonly known as "shingles," occurs following re-activation of the varicella zoster virus. It contributes a large cost burden to the U.S. health care system, with an estimated 1 million cases costing $1 billion annually. The current gold standard treatment is acyclovir, which limits viral replication. However, acyclovir has been reported to cause neurotoxicity in patients with acute or chronic kidney (...) disease.This case presents an occurrence of acyclovir-induced toxic encephalopathy in a patient with normal renal function. A 63-year-old male presented to the emergency department with ataxia, tremors, fluctuating aphasia, confusion, agitation, and fatigue. Results of imaging, lumbar puncture, and laboratory studies directed clinicians toward acyclovir toxicity, despite a normal creatinine level. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Emergency physicians will likely be the first point

2019 Journal of Emergency Medicine

14. Valaciclovir versus aciclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients [Cochrane Protocol]

Valaciclovir versus aciclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

15. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. Full Text available with Trip Pro

Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. This study investigated the safety and efficacy of famciclovir compared to acyclovir in patients with herpes zoster, to determine whether the two regimens are equally effective for the treatment of patients with uncomplicated herpes zoster over a period of 7days.Patients were randomly assigned to receive either famciclovir 500mg (one tablet) three times daily or acyclovir 800mg (two capsules (...) completed treatment (n=75 famciclovir, n=76 acyclovir). A similar proportion of patients who received acyclovir (94.74%) and famciclovir (94.67%) achieved complete cure. The mean time to full crusting of herpes zoster lesions was 15.033days in the acyclovir group and 14.840days in the famciclovir group (log-rank p-value=0.820). The most common adverse events in the pooled groups were headache, diarrhea, nausea, back pain, cold, and drowsiness, but none of these was deemed to be clinically important.Both

2018 International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases Controlled trial quality: predicted high

16. Acyclovir

LNC LP14522-4, MTHU006764 English Aciclovir , Acycloguanosine , 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)- , Aciclovir [eyes] , Aciclovir [skin] , Aciclovir [systemic] , Acyclovir [eyes] , Acyclovir [skin] , Acyclovir [systemic] , 9-((2-Hydroxyethoxy)methyl)guanine , 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one , 9-[(2-Hydroxyethoxy)methyl]guanine , acyclovir , ACV , Ophthalmic form aciclovir , Ophthalmic form acyclovir (product) , Ophthalmic form acyclovir (...) , acyclovir (medication) , ACYCLOVIR , Acyclovir [Chemical/Ingredient] , aciclovir , Aciclovir - chemical , Aciclovir - chemical (substance) , Aciclovir [systemic] (product) , Aciclovir [eyes] (product) , Aciclovir [skin] (product) , 9-[(2-Hydroxyethoxy)-methyl]guanine , Acyclovir (product) , Acyclovir (substance) , acycloguanosine , Acyclovir , Aciclovir [eyes] (substance) , Aciclovir [skin] (substance) , Aciclovir [systemic] (substance) Swedish Aciklovir Czech acykloguanosin , acyklovir Spanish

2018 FP Notebook

17. Comparative Study with a Lip Balm Containing 0.5% Propolis Special Extract GH 2002 versus 5% Aciclovir Cream in Patients with Herpes Labialis in the Papular/Erythematous Stage: A Single-blind, Randomized, Two-arm Study Full Text available with Trip Pro

Comparative Study with a Lip Balm Containing 0.5% Propolis Special Extract GH 2002 versus 5% Aciclovir Cream in Patients with Herpes Labialis in the Papular/Erythematous Stage: A Single-blind, Randomized, Two-arm Study This controlled single-blind trial compared the efficacy of a lip balm with propolis special extract GH 2002 at a concentration of 0.5% in the treatment of episodes of herpes labialis with that of 5% aciclovir cream.Patients in the erythematous/papular stage were randomized: 189 (...) patients were treated with propolis cream, 190 patients were treated with aciclovir cream (intention-to-treat population). Application was 5 times daily. The primary parameter was the difference in median time to complete encrustation or epithelialization of lesions. Secondary parameters were the development of typical herpes symptoms (eg, pain, burning and itching, tension, and swelling), the global assessment of efficacy, and the safety of application.The predefined clinical situation was reached

2017 Current therapeutic research, clinical and experimental Controlled trial quality: uncertain

18. Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity

Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02879630 Recruitment Status : Recruiting First Posted : August 25, 2016 Last Update Posted : May 30

2016 Clinical Trials

19. Comparison of Acyclovir and Famciclovir for Ramsay Hunt Syndrome. (Abstract)

Comparison of Acyclovir and Famciclovir for Ramsay Hunt Syndrome. Although antiviral agents are widely used to treat Ramsay hunt syndrome (RHS), their relative effectiveness has not been assessed. This study retrospectively compared clinical outcomes in patients with RHS treated with the antiviral agents acyclovir and famciclovir.This study involved 227 patients diagnosed with RHS from 2003 to 2015. Patients were treated with prednisolone plus acyclovir (n = 102) or famciclovir (n = 125 (...) ). Patient outcomes were measured using the House-Brackmann scale according to age, initial severity of disease, electroneurography, and underlying disease.Based on complications (p = 0.019) and disease severity (p = 0.013), the overall complete recovery rate was significantly higher with famciclovir than with acyclovir, whereas rates of recovery in patients with severe (p = 0.111) and initially moderate (grades III-IV; p = 0.070) facial palsy were similar. Electroneurography also showed no difference

2017 Otology and Neurotology

20. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study. Full Text available with Trip Pro

Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study. Although acyclovir prophylaxis against varicella zoster virus (VZV) infection for ≥1 year is recommended after allogeneic hematopoietic cell transplantation (HCT), the emergence of acyclovir-resistant viruses and adverse drug effects cannot be ignored. We investigated the cumulative incidence of VZV infection after (...) allogeneic HCT in children receiving a shorter duration of acyclovir prophylaxis than recommended and evaluated the appropriateness of the short duration of acyclovir prophylaxis.Medical records of 217 children who received allogeneic HCT were retrospectively reviewed until a median of 25 months (range = 1-59 months) after HCT. Acyclovir prophylaxis was given for a median of 9 weeks (range = 3-24 weeks) after HCT.VZV infection was diagnosed in 33 (15.2%) children at a median time of 5 months (range = 2

2017 Medicine